medigraphic.com

2000, Number 2

<< Back Next >>

Vet Mex 2000; 31 (2)

Isolation and molecular characterization of rabies virus from a non-hematophagous bat in Mexico City

Sumano LH, Gutiérrez OL

Language: English/Spanish
References: 38
Page: 137-145
PDF size: 62.15 Kb.


ABSTRACT

Hace más de dos décadas se introdujo a México y a gran parte de Latinoamérica la enrofloxacina, un derivado fluorínico, considerado el antibacteriano más potente descubierto a la fecha en medicina veterinaria. Su uso, inicialmente a dosis de 5 mg/kg/día de una presentación al 5% y más recientemente a dosis de 10 mg/kg/día de una presentación al 10%, sugiere el inicio de la aparición de resistencias bacterianas y de reducción de su eficacia clínica. Sin embargo, la proliferación de presentaciones similares de dudosa calidad, así como el uso clínico descuidado, en campo, de este antibacteriano puede contribuir, aún más que las resistencias bacterianas, a la disminución de la eficacia percibida (no demostrada) por el clínico. En este artículo se presenta un punto de vista sobre el uso y abuso de uno de los medicamentos de más valor en la historia de la medicina veterinaria, en particular para la industria avícola, la enrofloxacina. El principal objetivo de este trabajo es revisar aspectos farmacológicos básicos de la enrofloxacina y orientar al clínico para que haga buen uso del medicamento, al tiempo que se compara el estado actual del uso de este antibacteriano en otras partes del mundo.


REFERENCES

  1. 1. Prescott JF. Antimicrobial susceptibility testing and antimicrobial drug dosage. J Am Vet Med Assoc 1980;10: 1085-1090.

  2. 2. Blanco JE, Blanco M, Mora A, Blanco J. Prevalence of bacterial resistance to quinolones and other antimicrobials among avian Escherechia coli strains isolated from septicemic and healthy chickens in Spain. J Clin Microbiol 1997;5:2184-2185.

  3. 3. Baggot JD. Distribution of antimicrobial agents in normal and diseased animals. J Am Vet Med Assoc 1980;10:1085-1090.

  4. 4. Prescott JF, Baggot JD. Antimicrobial therapy in veterinary medicine. 2nd ed. Ames (Io): Iowa State University Press, 1993.

  5. 5. Sumano LH. Quinolonas y fluoroquinolonas en medicina veterinaria. Vet Méx 1993;2: 23-34.

  6. 6. Goater E. Utilisation des antifectieux dans l’espèce poule. L’Aviculteur 1988;486:1-12.

  7. 7. Puyt JD. Antibiotic therapy in poultry production. Bulletin-dans- G T V 1995;5:17-109.

  8. 8. Russel ID. Proper water medication with good water systems. Poultry Digest 1992;54:40-48.

  9. 9. Wages DP. Proper medication procedures. Poultry Digest 1997;56:18-19.

  10. Rodríguez-García R. Evaluación de la mezcla enrofloxacina trimetroprim in vitro (tesis licenciatura). México (DF): México: Facultad de Medicina Veterinaria y Zootecnia. UNAM, 1997.

  11. Randandt JM, Randall MC, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infec Dis 1992;14:272-284.

  12. Dorrestein DJ, Van Miert ASJPAM. Pharmacotherapeutic aspects of medication of birds. J Vet Pharmacol Ther 1988;11:33-44.

  13. Prukner Rodovcic E; Rukavina V; Mazija H; Prpic B. Effect of quinolones (enrofloxacin) on the productivity and immune status of brailers. (Ucinak kinolona na prozvodna svojsta I na zdravlje imunog sustavo-tovih pilica). Praxis Veterinaria Zagreb. 1993;41:143-153.

  14. Medders WM, Wooley RE, Gibbs PS, Shotts EB, Broen J. Mutation rate of avian intestinal coliform bacteria when pressured with fluoroquinolones. Avian Dis 1998; 1:146-53.

  15. Abd el Aziz MI, Agag AE. Influence of some antibiotics used as growth promotors on immune response of chickens. Assiut Vet Med J 1996;35:64-75.

  16. Koenraad PMFJ, Jacobs-Reitsma WF, Laan Van Der T, Beumer RR, Rombouts FM. Antibiotic susceptibility of Campylobacter isolates from sewage and poultry abattoir drain water. Epidemiol Infec 1996;115:475-483.

  17. Nikolovski J, Nikolovski-Stefanovic Z, Damnjanovic N, Kaluderovic V. Selection and application of antibiotics in treatment of bacterial diseases in poultry. Zivinarstvo 1997;32:207-211.

  18. Piddock LJV, Wray C, McClaren I, Wise R. Quinolone resistance in Salmonella sp.: veterinary pointers. Lancet 1995;336:125.

  19. Shlosberg A, Ershov E, Bellaiche M, Hanji V, Weisman Y, Soback S. The effects of enrofloxacin on hepatic microsomal mixed function oxidase in broiler chickens. J Vet Pharmacol Ther 1995;18:311-313.

  20. Sumano LH, Gracia MI, Romero V, Ruiz-Ramirez L. The use of ciprofloxacin in proprietary products of enrofloxacin. Vet Hum Toxicol 1994;5:476-477.

  21. Sumano LH, Ocampo CL. Compositional analysis surveillance of eleven trade brands of enrofloxacin including Baytril, for veterinary use. J Vet Med 1995:7:152-178.

  22. Sumano LH, Ocampo CL, Farmacología veterinaria. 2ª ed. México. (DF): McGraw-Hill-Interamericana, 1997.

  23. Aramayona JJ, Mora J, Fraile LJ. Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drug in lactating rabbits and neonatal of offspring. Am J Vet Res 1996;4:547-53.

  24. Shenl L, Pernet AG. Mechanism of inhibition of DNA gyrase by quinolone antibacterials; specificity and cooperativity of drug binding the DNA. Biochemistry 1989;28: 3879-3885.

  25. Abd-el-Aziz MI, Azis MA, Soliman FA, Afify NA. Pharmacokinetic evaluation of enrofloxacin in chickens. British Poultry. Vet Med Rev 1987;2:130-136.

  26. Andon A, Martinez MR, Diaz MJ, Bringas P, Martinez MA, Fernandez-Cruz ML, Fernandez MC, Fernandez R. Pharmacokinetics and residues of enrofloxacin in chickens. Am J Vet Res 1995;56:501-506.

  27. Anne E, Asuquo J, Piddock V. Accumulation and killin kinetics of fifteen quinolones for Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother 1993;31;865-880.

  28. Brown SA. Fluoroquinolones in animal health. J Vet Pharmacol Ther 1996;19:1-14.

  29. Intorre L, Mengozzi G. Bertini S, Bagliacca M, Luchetti E, Soldani G. The plasma kinetics and tissue distribution of enrofloxacin and metabolite ciprofloxacin in the Muscovy duck. Vet Res Commun 1997;21:127-136.

  30. Hubert E, Mouton PR, Van Der Reyden T, Ruijus GJ, Biever M. Fluoroquinolone resistance in Campylobacter sp isolated for human stools and poultry products. Lancet 1997;335:787.

  31. Koenrad PMJF, Jacobs-Reitsman WF. LaanT, Beumer RR, Pombouts FM. Antibiotics susceptibility of Campylobacter isolated from sewage and poultry abattoir drain water. Epidemiology 1995;115:475-483.

  32. Kho HB, Kang MI, Kim GN. Antimicrobial drugs susceptibility of Mycoplasma gallisepticum isolated from chronic respiratory diseases outbreaks. Korean J Vet Public Health 1993;17:63-68.

  33. Garcia-Ovando H, Luders C, Gorla N, Errecalde C, Prieto G. Intravenous pharmacokinetics of enrofloxacin and ciprofloxacin in broiler chickens. Proceedings of the 7th European Association for Veterinary Pharmacology and Toxicology International Congress; 1997 July 6-10. Madrid, Spain. Jvet Pharmacol Ther. 1997;20(suppl):203-204.

  34. Kietzmann M, Knoll U, Glunder G. Pharmacokinetics of enrofloxacin and danofloxacin in broiler chickens. J Vet Pharmacol Ther 1997;20(suppl):202.

  35. Andon A, Martinez-Larrañaga MR, Diaz MJ, Velez C, Bringas P, Pharmacokinetic and residue studies of quinolone compounds and olaquindox in poultry. Ann Rech Vet 1990:21:137-144.

  36. Erdeger J, Diker KD. Multiple antibiotic resistance in poultry isolates of Campylobacter. J Antimicrob Chemother 1991;27:199-208.

  37. Aarestrup FM, Nielsen EM, Madsen M, Engberg J. Antimicrobial susceptibility patterns of thermophilic Campylobacter spp. for humans, pigs, cattle and broilers in Denmark. J Antimicrob Agents Chemother 1997;41: 2244-2250.

  38. Jacobs-Reitsman WF, Koenraad PMFJ, Bolder NM, Mulder RWAW. In vitro susceptibility of Campylobacter and Salmonella isolates from broilers to quinolones, ampicillin, tetracycline and erytromicine. Vet Q 1994;4: 199-208.




2020     |     www.medigraphic.com